Faruqi & Faruqi Investigates REGENXBIO Investor Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy RGNX?
Source: PRnewswire
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating REGENXBIO for potential claims regarding investor losses incurred between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
- Investor Rights Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who have suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with two phone numbers provided to ensure affected investors can receive legal advice and support.
- Potential Litigation Risks: This investigation could lead to a class action lawsuit against REGENXBIO, and if the findings confirm wrongdoing, it may negatively impact the company's reputation and stock price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.360
Low
19.00
Averages
29.71
High
45.00
Current: 8.360
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates REGENXBIO Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating REGENXBIO for potential claims related to investor losses incurred between February 9, 2022, and January 27, 2026, indicating possible legal liabilities that could impact the company's market reputation.
- Investor Rights Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information regarding their legal options, demonstrating the firm's commitment to client service.
- Potential Claim Risks: As the investigation progresses, REGENXBIO may face claims that could affect its stock price and investor confidence, leading to future legal and financial risks, prompting investors to closely monitor developments.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy clinical trial, providing false and misleading information that led to investor losses when the truth was revealed, adversely affecting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could negatively impact the outcome of the litigation.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and potentially receive compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, ensuring that investor rights are protected without financial risk.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this legal domain.
See More
Class Action Lawsuits Filed Against PayPal and REGENXBIO
- PayPal Lawsuit Overview: A class action lawsuit has been filed on behalf of PayPal Holdings, Inc. shareholders for the period from February 25, 2025, to February 2, 2026, alleging that the company misrepresented its revenue outlook, resulting in a stock price drop of over 20% following the February 3, 2026 earnings announcement.
- Disappointing Financial Performance: On February 3, 2026, PayPal reported its fiscal year 2025 results, revealing worsening performance in Branded Checkout and retracting its 2027 financial targets, highlighting challenges from macroeconomic factors and competitive pressures.
- REGENXBIO Lawsuit Context: Shareholders of REGENXBIO Inc. have initiated a class action for the period from February 9, 2022, to January 27, 2026, alleging that the company concealed adverse facts regarding the safety and efficacy of its RGX-111 gene therapy trial, misleading investors.
- FDA Clinical Hold Impact: On January 28, 2026, REGENXBIO announced that the FDA had placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a trial participant, causing the stock price to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, indicating significant investor concern regarding the company's transparency and accountability.
- False Statements Allegations: The complaint claims that REGENXBIO made materially misleading statements about its RGX-111 gene therapy development, particularly regarding the anticipated success of its clinical trials, which lacked a reasonable basis, potentially undermining investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by April 14, 2026, highlighting the law firm's commitment to safeguarding investor rights and reflecting the market's increasing emphasis on corporate governance and transparency.
- No-Cost Legal Services: The law firm offers legal representation on a contingency fee basis, meaning they will only charge fees if successful in recovering damages, thereby reducing the financial burden on investors and encouraging greater participation in the lawsuit.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses once the truth was revealed.
- Market Reaction: Following the revelation of Regenxbio's misleading statements, investor losses increased significantly, indicating a major failure in the company's disclosure practices that could undermine future investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected shareholders to join the lawsuit for compensation, demonstrating the firm's commitment to protecting investor rights.
See More
Faruqi & Faruqi Investigates REGENXBIO Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating REGENXBIO for potential claims related to investor losses incurred between February 9, 2022, and January 27, 2026, indicating possible legal liabilities that could impact the company's market reputation.
- Investor Rights Reminder: The firm reminds investors that April 14, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their legal rights.
- Direct Contact Channels: Investors can reach out directly to attorney Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information regarding their legal options, demonstrating the firm's commitment to client service.
- Potential Claim Risks: As the investigation progresses, REGENXBIO may face claims that could affect its stock price and investor confidence, leading to future legal and financial risks, prompting investors to closely monitor developments.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Initiation: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy clinical trial, providing false and misleading information that led to investor losses when the truth was revealed, adversely affecting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Guidance: Investors are advised to select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could negatively impact the outcome of the litigation.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Deadline: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, that they must apply to be lead plaintiff by April 14, 2026, to participate in the class action and potentially receive compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, ensuring that investor rights are protected without financial risk.
- Case Background: The lawsuit alleges that defendants provided false and misleading information regarding REGENXBIO's RGX-111 gene therapy development, resulting in investor losses when the true facts emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this legal domain.
See More
Class Action Lawsuits Filed Against PayPal and REGENXBIO
- PayPal Lawsuit Overview: A class action lawsuit has been filed on behalf of PayPal Holdings, Inc. shareholders for the period from February 25, 2025, to February 2, 2026, alleging that the company misrepresented its revenue outlook, resulting in a stock price drop of over 20% following the February 3, 2026 earnings announcement.
- Disappointing Financial Performance: On February 3, 2026, PayPal reported its fiscal year 2025 results, revealing worsening performance in Branded Checkout and retracting its 2027 financial targets, highlighting challenges from macroeconomic factors and competitive pressures.
- REGENXBIO Lawsuit Context: Shareholders of REGENXBIO Inc. have initiated a class action for the period from February 9, 2022, to January 27, 2026, alleging that the company concealed adverse facts regarding the safety and efficacy of its RGX-111 gene therapy trial, misleading investors.
- FDA Clinical Hold Impact: On January 28, 2026, REGENXBIO announced that the FDA had placed a clinical hold on RGX-111 due to the discovery of an intraventricular CNS tumor in a trial participant, causing the stock price to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, indicating significant investor concern regarding the company's transparency and accountability.
- False Statements Allegations: The complaint claims that REGENXBIO made materially misleading statements about its RGX-111 gene therapy development, particularly regarding the anticipated success of its clinical trials, which lacked a reasonable basis, potentially undermining investor confidence in the company's future prospects.
- Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by April 14, 2026, highlighting the law firm's commitment to safeguarding investor rights and reflecting the market's increasing emphasis on corporate governance and transparency.
- No-Cost Legal Services: The law firm offers legal representation on a contingency fee basis, meaning they will only charge fees if successful in recovering damages, thereby reducing the financial burden on investors and encouraging greater participation in the lawsuit.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made misleading statements regarding its product candidate RGX-111, concealing negative efficacy and safety data, which led to significant investor losses once the truth was revealed.
- Market Reaction: Following the revelation of Regenxbio's misleading statements, investor losses increased significantly, indicating a major failure in the company's disclosure practices that could undermine future investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and encourages affected shareholders to join the lawsuit for compensation, demonstrating the firm's commitment to protecting investor rights.
See More
